Artificial Pancreas Market Size

Artificial Pancreas Market Overview

Artificial Pancreas Market Size was valued at USD 4.5 Billion in 2023. The Global Artificial Pancreas industry is projected to grow from USD 5.7 Billion in 2024 to USD 13.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.02% during the forecast period (2024 - 2032).

April 2024: Bigfoot Biomedical acquired a strategic partner specialized in glucose monitoring technologies. Consequently, this purchase is anticipated to augment Bigfoot’s capacity to develop integrated diabetes management solutions, including advanced artificial pancreas systems.

May 2024: Beta Bionics combined efforts with a biotechnology firm to accelerate the development of iLet bionic pancreases. Therefore, the deal aims at increasing innovation and advancing more sophisticated solutions for the prevention and treatment of diabetes.

February 2024: Tandem Diabetes Care, Inc., through acquisition, became one of the best producers of insulin pumps globally. Thus this merger is projected to assist Tandem in broadening its product line as well as reinforcing its position in the market for artificial pancreas devices systems.

January 2024: Pancreum, Inc., upon exhibiting its latest artificial pancreas called Beta-Pump X1 containing algorithms based on machine learning (ML) to personalize insulin doses, put forward a product which intends to enhance life quality among people suffering from diabetes mellitus.

At ATTD’S International Conference on Advanced Technologies & Treatments for Diabetes held recently, multiple center randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) presented positive results by Beta Bionics, Inc., a medical technology company dedicated to design, development and commercialization of the iLet Bionic Pancreas.

In March 2022, Medtronic hit the Indian market with their MiniMed 780G, next-generation closed-loop insulin pump system.

In May 2021, the FDA approved the Bigfoot Biomedical initiative, whose goal was to provide a pen-like device for administering insulin in diabetes patients who prefer injections as the option to an insulin pump.

Likewise, in September 2020, there was approval by US FDA of a hybrid closed-loop insulin delivery system (the next generation) for children aged between 2 and 6 years suffering from type I diabetics.

For instance, the US Food and Drug Administration gave clearance to Medtronic plc’s MiniMed 770G Hybrid Closed Loop HCL System in September 2020. Specifically, it is a more advanced version of MiniMed®670G that has smartphone connectivity and covers a wider age range starting from two years. These changes are set to boost market expansion.

Artificial pancreas are devices that mimics the glucose regulating function of healthy pancreas. These devices use computer-controlled algorithm so as to precisely calculate the amount of insulin to be delivered by using an insulin infusion pump. Advanced products can deliver bi-hormones so as to avoid excessive fall in blood sugar and more closely mimic the working of healthy pancreas with little or no input from the patient.

A glucose monitor and an insulin infusion pump are connected by a medical device known as an artificial pancreas device system, which causes the pump to function automatically (using a control algorithm) in response to the glucose monitor reading. The drivers driving the market growth are the intense R&D activities by industry participants, increased prevalence of diabetes, and expanding demand for automated systems for glycemic management. Patients with diabetes are monitored for blood glucose levels using artificial pancreas device systems (APDS), and industry participants are conducting several studies to improve diabetes treatment. Since these devices are less invasive, a larger portion of the patient uses them. The rising senior population, rising obesity prevalence and rising diabetes incidence are mostly to blame for the market's expansion.

Several other factors are also actively influencing the development of the analyzed market, including the rising prevalence of diabetes, technical improvements, an increase in key players' R&D efforts, and rising demand for automated glycemic control systems. As a result, given the data and major driving forces, the artificial pancreas device system industry is estimated to soar over the projected time. Since type 1 diabetics benefit most from artificial pancreas use. Devices known as artificial pancreas imitate the healthy pancreas' ability to regulate blood sugar. These instruments use computer-controlled algorithms to accurately determine how much insulin needs to be administered via an insulin infusion pump. Advanced solutions can provide bi-hormones to prevent a sharp drop in blood sugar levels and more accurately replicate the actions of healthy hormones. The increased prevalence of diabetes is anticipated to grow in the market under investigation. Technology developments, rising product approval rates, partnerships, and collaborations between important players, as well as other factors, all contribute to the market's expansion.

News: An artificial pancreas created at the Medical School of Virginia Center for Diabetic Technology helps type 1 diabetic children between the ages of 2 and 6 better control their blood sugar levels. The esteemed New England Journal of Medicine has just published the specifics of the clinical trial and its findings. Comparing those in the control group who continued to rely on the methods they had been using to control their blood sugar, trial participants utilizing the artificial pancreas worked about three more hours per day in the desired glucose range. Tandem Diabetes Care developed the Control-IQ system, a diabetes care tool that constantly monitors and controls blood glucose.

Key players of Artificial Pancreas Market:

• Medtronic


• Johnson & Johnson


• Beta Bionics


• Admetsys (pipeline product analysis)


• Animas Corporation


• Defymed


• dexcom


• Insulet


• medtech


• Bigfoot Biomedical


• Semma Therapeutics


• Tandem Diabetes Care


• TypeZero Technologies

Intended Audience

• Global Artificial Pancreas, manufacturers & suppliers


• Research and development (R&D) companies


• Market research and consulting service providers


• Academic institutes and universities

Artificial Pancreas Segments

The artificial pancreas market is segmented on the basis of type and end users. 

Based on type

The market has been segmented as threshold suspend device system, non-threshold suspend device system, control-to-range (CTR) system, and control-to-target (CTT) system. 

Based on the treatment type

The market has been segmented as insulin only, bi-hormonal, and hybrid. 

Based on the end users

The market has been segmented as hospitals and clinics, research, and others.

News: The 780G automated insulin administration system from Medtronic Minimed with the Guardian 4 sensor has received approval from the US Food and Drug Administration. The most recent "artificial pancreas" device has been authorized for type 1 diabetics aged 7 and older. On May 15, 2023, Medtronic will start accepting preorders for the 780G.

Regional analysis

US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global artificial pancreas. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most potential which is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.

Study objectives:

• To provide a detailed analysis of the market structure along with estimated future growth forecast for the next six years about various segments and sub-segments of the Artificial Pancreas market.


• To provide insights about factors affecting the artificial pancreas market growth.


• To analyze the Artificial Pancreas market based on various factors - Price Analysis, Supply Chain Analysis, Porters Five Force analysis etc.


• To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries - the Americas, Europe, Asia Pacific along with Middle East & Africa.


• To provide country level analysis of the market with respect to the current market size and future growth prospects.


• To provide country level analysis of the market which includes segmentation by type, treatment type and end users.


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the market.


• To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments that are currently taking place in the artificial pancreas markets.

Research methodology

The report for Artificial Pancreas Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The artificial pancreas market report also gives a broad study of the different market segments and regions.